Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | MITF | O75030 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7371438 | 0.92 | MEN1 (0.51) | ALDH1A1HTTMITFSMN1; SMN2KDM4E | |
| SCHEMBL5725403 | 0.86 | ALDH1A1 (0.43) | ALDH1A1SIGMAR1CHRM2CHRM3ADRA1A | |
| SCHEMBL2037132 | 0.85 | ALDH1A1 (0.51) | ALDH1A1HTTTAAR1MITFSMN1; SMN2 | |
| SCHEMBL16335464 | 0.83 | HTT (0.44) | ALDH1A1HTTTAAR1MITFSMN1; SMN2 | |
| SCHEMBL2340823 | 0.78 | ALDH1A1 (0.43) | ALDH1A1HTTTAAR1MITFSMN1; SMN2 | |
| SCHEMBL3402515 | 0.78 | OPRM1 (0.44) | ALDH1A1HTTTAAR1MITFSMN1; SMN2 | |
| SCHEMBL3409354 | 0.74 | HDAC1 (0.45) | ALDH1A1HTTSMN1; SMN2MEN1NPC1 | |
| SCHEMBL11344206 | 0.74 | KMT2A (0.48) | ALDH1A1HTTMITFSMN1; SMN2KDM4E | |
| SCHEMBL3404199 | 0.74 | MEN1 (0.49) | ALDH1A1HTTMITFSMN1; SMN2KDM4E | |
| SCHEMBL11671526 | 0.73 | KDM4E (0.50) | ALDH1A1HTTMITFSMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2177502-A1 | Compounds and their use | Oryzon Genomics, S.A. (ES) | 2010-04-21 | — | — | EP | claimed |
| EP-3397616-B1 | LSD1 INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2020-06-10 | — | — | EP | disclosed |
| EP-3105219-B9 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORP (US) | 2018-10-03 | — | — | EP | disclosed |
| EP-2361242-B1 | OXIDASE INHIBITORS AND THEIR USE | ORYZON GENOMICS SA (ES) | 2018-08-01 | — | — | EP | disclosed |
| EP-3105219-B1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORP (US) | 2018-04-11 | — | — | EP | disclosed |
| US-8524717-B2 | Oxidase inhibitors and their use | ORYZON GENOMICS, S.A. (ES) | 2013-09-03 | — | — | US | disclosed |
| US-8524717-B2 | Oxidase inhibitors and their use | ORYZON GENOMICS, S.A. (ES) | 2013-09-03 | — | — | US | disclosed |
| US-20110263604-A1 | Oxidase inhibitors and their use | ORYZON GENOMICS, S.A. (ES) | 2011-10-27 | — | — | US | disclosed |
| US-20110263604-A1 | Oxidase inhibitors and their use | ORYZON GENOMICS, S.A. (ES) | 2011-10-27 | — | — | US | disclosed |
| EP-2361242-A1 | OXIDASE INHIBITORS AND THEIR USE | Oryzon Genomics, S.A. (ES) | 2011-08-31 | — | — | EP | disclosed |
| EP-2361242-A1 | OXIDASE INHIBITORS AND THEIR USE | Oryzon Genomics, S.A. (ES) | 2011-08-31 | — | — | EP | disclosed |
| WO-2010043721-A1 | OXIDASE INHIBITORS AND THEIR USE | ORYZON GENOMICS, S.A. (ES) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010043721-A1 | OXIDASE INHIBITORS AND THEIR USE | ORYZON GENOMICS, S.A. (ES) | 2010-04-22 | — | — | WO | disclosed |
| EP-2177502-A1 | Compounds and their use | Oryzon Genomics, S.A. (ES) | 2010-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263604-A1 | Oxidase inhibitors and their use | MAOA, PNPO, MAOB | ALDH1A1 127/4885HTT 2541/4885TAAR1 919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.